Introduction
The treatment of non-small cell lung cancer (NSCLC) is challenging, but several new targeted agents are emerging from the pipeline. At the same time, oncologists face the prospect of new types of adverse events, among them ocular toxicity. Although targeted agents are directed against aberrations in tumor cells, they are associated with toxicities affecting multiple organs, including the eye, as a result of target expression in ocular and eyelid tissue.
Ocular toxicity (Table 1) is generally underestimated and considered minor. Nevertheless, oncologists must be challenged to recognize clinical cases and understand how to manage them; it is also important that oncologists refer to the ophthalmologist when the complexity of clinical status require a specialistic evaluation. Some ocular toxicity (e.g., conjunctivitis) may be diagnosed during a normal physical examination whereas retinal damage requires a specialist ophthalmologic examination.
Ocular toxicities are grouped in the CTC-AE [5] for ocular toxicity, which mainly takes into account interference with the activities of daily living, as for other adverse events. However, while for chemotherapeutics, toxicities are generally short lived and the intensity can be considered a good marker for intervention, toxicities for targeting agents can be long lasting albeit of relatively mild intensity, and the existing systems for recording are not adequate for measuring patient unease.
At present, with new investigational agents with known preclinical ocular toxicity observed in animal models, clinical trials include specialist ophthalmologic visits; this is mandatory as part of many study protocol procedures.
Ophthalmological toxicities arising from chemotherapy
The ocular complications associated with cancer chemotherapeutics have been described in three major systematic reviews 0305 [1] [2] [3] , but none has specifically focused on NSCLC patients. Here we review only toxicities related to approved chemotherapeutics for NSCLC and that are commonly used by oncologists in their daily clinical practice, referring both to the adjuvant and to the metastatic setting.
Cisplatin is a heavy metal compound and the cornerstone of several antitumor therapies. All the main clinical guidelines (American Society of Clinical Oncology (ASCO) [6] and European Society of Medical Oncology (ESMO) [7] ) recommend a first-line cisplatinbased chemotherapy as the treatment of choice in the advanced and adjuvant setting. Drugs that may be combined with platinum include the third-generation cytotoxic drugs docetaxel, gemcitabine, irinotecan, paclitaxel, pemetrexed, vinorelbine and etoposide (just for small-cell lung cancer). Neurotoxicity represents the major dose-limiting toxicity of cisplatin. The neuropathy is uncommon below a cumulative cisplatin dose of 400 mg/m 2 but nearly universal in the cumulative-dose range of 600-800 mg/m 2 . The cumulative dose that causes peripheral neuropathy tends to be higher in children and younger patients than in the elderly and the risk of neurotoxicity is higher in patients with renal dysfunction [8] [9] [10] . Visual impairment has been considered an infrequent form of cisplatin neurotoxicity. Case reports have attributed visual alterations to optic neuritis and cortical blindness, which have sometimes been accompanied by seizure activity [11] [12] [13] [14] . Ocular toxicity has generally been reported after the use of regimens with higher doses or greater dose frequencies than those recommended by the manufacturer. Improvement and/or total recovery usually occurs after discontinuation of cisplatin [15] . An alert of possibly cisplatininduced retinal ischemia was reported by Kwan in 2006 [16] .
Intravenous administration of carboplatin is less frequently associated with ocular disturbances, and a few cases of maculopathy, optic neuropathy, cortical blindness, sore eyes, blurred vision, and chorioretinitis to optic neuritis have been reported [17] [18] [19] . In any case, visual disturbances were reversible after drug cessation.
Pemetrexed is an antifolate chemotherapeutic agent. The antitumor activity of this agent likely derives from inhibition of several key folate-requiring enzymes, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. The drug is currently approved for the treatment of pleural mesothelioma combined with a platinum compound and for first-and second-line therapy in advanced NSCLC with nonsquamous histology. The only well-known drug-related ocular adverse event is conjunctivitis, also a common adverse effect of other antimetabolite antineoplastic agents such as cytosine arabinoside, 5-fluorouracil, and methotrexate [20, 1, 21] . This disturbance is generally associated with hyperemia, irritation, and serous secretions. It has been reported in less than 5% of mesothelioma-naïve patients who were randomly assigned to receive cisplatin in combination with pemetrexed or single-agent cisplatin, with the same incidence in the two arms. Another case has been documented in which a patient received pemetrexed as third-line therapy for NSCLC advanced disease and developed conjunctivitis; this was a cutaneous adverse event that consisted of the simultaneous occurrence of periorbital edema, conjunctivitis, and inflammatory edema of the upper and lower limbs [22] .
Several prophylactic approaches have been investigated in the prevention of antimetabolite-induced conjunctivitis. Matteucci et al., [23] investigated in a randomized trial the efficacy of dexamethasone in combination with diclofenac eye drops as prophylaxis for conjunctivitis induced by high-dose cytosine arabinoside. They concluded that the combination of dexamethasone/diclofenac therapy compared with dexamethasone alone significantly prevented drug-induced conjunctivitis (incidence 13% vs. 45% respectively; p 6 0.09). Treatment of drug-induced conjunctivitis usually involves the use of artificial tears, withdrawal of the agent wich determined the toxicity, and a short course of topical steroids, and is typically curative [1, 21] , even though, most of the time, the conjunctivitis is recurrent despite symptomatic treatment. Steroideal therapy (topical or systemical) should be administered only if a possible infectious has been eliminated.
Gemcitabine has structural similarities to the other antimetabolite chemotherapeutic drugs so that ocular toxicities cannot be completely excluded. The drug is currently approved for the treatment of advanced disease and commonly used in the locally advanced and metastatic settings. Only one case of a drug-related visual serious adverse event has been reported,identified as a Purtscher retinopathy [24] . This is a rare syndrome characterized by the appearance of a vaso-occlusive retinal injury and concomitant presence of cutaneous vasculitis; this retinopathy was associated with digital necrosis and antinuclear antibody elevation. Another case report [25] of gemcitabine-induced retinopathy in a diabetic patient presented with retinal changes that included aneurysms, cotton-wool spots, intraretinal hemorrhages, and vascular leakage on fluorescein angiogram; clinical improvement after gemcitabine withdrawal and relapse of retinopathy from re-exposure strongly suggested gemcitabine to be causative of the disorder.
Docetaxel is an effective chemotherapeutic agent that is widely used in the treatment of locally advanced and metastatic NSCLC. Canalicular and nasolacrimal duct obstruction possibly due to stromal fibrosis are well-known ocular side effects of docetaxel [26] . Epiphora due to canalicular stenosis in patients treated with weekly docetaxel was first reported by Esmaeli et al., [27] . Nasolacrimal duct obstruction secondary to treatment with docetaxel may be partly due to stromal fibrosis in the mucosal lining of the lacrimal drainage apparatus. These changes are consistent with a previous preclinical observation that docetaxel is excreted via the lacrimal glands. Early detection is important to prevent irreversible stenosis that would require surgical intervention by dacryocystorhinostomy. Skolnik and Doughman [28] also reported a case of erosive conjunctivitis and punctual stenosis secondary to docetaxel administration; the erosive conjunctivitis resolved after drug discontinuation.
Paclitaxel is as widely used as docetaxel in the treatment of local and metastatic NSCLC. This drug is known to produce neurotoxicity. Both transient and scintillanting scotoma and visual impairment have been reported with paclitaxel [29] . Photopsia usually appears during the last 30 min of the infusion and resolves completely within 3 h. It usually occurs in patients who receive doses of 250 mg/m 2 or more but rarely can develop at doses of 175 mg/m 2 given intravenously [30] . One of the rare side-effects caused by taxanes is a bilateral cystoid macular edema [31] ; it tends to be bilateral and can be confirmed by its biomicroscopic appearance on optical tomography scan, but the particularity of this kind of ocular disorder is that it is angiographically silent; fluorescin angiography demonstrated the unusual finding of the absence of localized retinal capillary leakage [32] . The mechanism of this edema is not clearly understood, and existing hypotheses do not explain this phenomenon very well. Very faint permeability of retinal vessels has been suggested as an explanation with a breakdown of the retinal blood-ocular barrier so minute that even a small fluorescein molecule cannot extrude or only minimally extrudes. Another possible pathogenic mechanism, suggested by Joshi and Garretson [33] , is a toxic effect of paclitaxel on Müller cells, which are responsible for maintaining osmotic gradients within the neurosensory retina, resulting in intracellular fluid accumulation. Some patients treated with paclitaxel develop visual evoked potential abnormalities typical of demyelinating optic neuropathy; a reversible scotoma was reported by Capri et al. [29] , and the abnormal visual evoked potential suggested an involvement of the optic nerve, comparable to the changes seen in ischemic neuropathies. Glaucoma also has been reported as a consequence of paclitaxel and docetaxel therapy [34, 35] . It is interesting to note that ophthalmologists have used an in vitro model for proliferative vitreoretinopathy to evaluate the action of paclitaxel on chorioretinal fibroblast proliferation and contractility. Proliferative vitreoretinoapthy results in retinal detachment and visual impairment due to fibroblastic proliferation in the vitreous and subsequent cellular contraction; dose-response curves obtained show paclitaxel to be a potent inhibitor of both cellular events [36] .
Vinorelbine is a plant alkaloid that stabilizes the microtubules by inhibiting the polymerization of tubulin, and the drug is currently approved for the treatment of advanced NSCLC. To our knowledge, no case of ocular toxicities has been reported with vinorelbine.
Ophthalmological toxicities arising from targeted therapies
At present, only agents targeting EGFR-and ALK-pathways have an established role for the treatment of advanced NSCLC. However, several targeted compounds are under investigation, and some of them have yielded promising results in the early phases of their development. Finally, no targeted agents have a role in the adjuvant setting.
Anti-EGFR agents
Agents targeting EGFR can be divided into at least two groups: EGFR tyrosine kinase inhibitors (TKIs) and EGFR-targeting monoclonal antibodies (mAbs). To date, only EGFR-TKIs and in particular gefitinib and erlotinib are commonly used in the clinical practice while afatinib and dacomitinib are now approaching this level of use.
Gefitinib and erlotinib are orally active EGFR-TKIs that selectively target HER1 (human epidermal growth factor receptor EGFR [ErbB1]). In preclinical toxicity studies of gefitinib at 40 mg/kg/day in rats and dogs, reversible thinning of corneal epithelium was observed in both species after 1 and 6 months. Furthermore, in dogs treated with the highest dose of gefitinib for 6 months, the corneal opacification first observed at one month progressed on treatment and did not reverse during a 3-month withdrawal period [37] . Other EGFR inhibitors have caused similar corneal changes in preclinical models, which are consistent with the pharmacological actions of gefitinib [38] . [39] . The prescribing information for gefitinib [40] notes that eye pathologies are common and include conjunctivitis, blepharitis,and eye dryness, events that can occur in association with other dryness scenarios (principally cutaneous reactions) of grade CTCAE 1 [5] . Uncommon ocular-related adverse events include reversible corneal erosion associated with eyelash growth. Although it appears to be a class effect associated with EGFR inhibitors, the occurrence of eyelash growth in relation to EGFR mutations is unknown; whether eyelash growth correlates with clinical response of lung cancer to EGFR inhibitors or whether it occurs as an unrelated adverse event remains to be evaluated on a larger scale. In addition, the prescribing information reports ''very rare'' cases of corneal membrane sloughing and ocular ischemia.
The prescribing information for erlotinib [41] notes that conjunctivitis and keratoconjunctivitis sicca each occurred in 12% of patients with NSCLC in one study [42] . Moreover, one patient in treatment with erlotinib plus chemotherapy developed corneal erosion/ulcer as an inflammatory mucous/cutaneous complication. Bilateral periorbital rash, conjunctivitis, and eyelid ectropion have been reported with erlotinib.
Afatinib (also called BIBW 2992) is a novel dual irreversible EGFR/HER2 TKI that has been shown in preclinical studies to potentially prevent, delay, or overcome resistance to reversible EGFRTKIs [43] ; the preclinical in vitro and in vivo activity profile includes EGFR mutant models with activating EGFR mutations, considering the most common mutations (L858R and deletion of exon 19) and also the exon 20 gatekeeper T790M mutation [44, 45] . The findings from these preclinical studies prompted the investigation of afatinib in patients with NSCLC and EGFR mutations (LUX-Lung program). Ocular toxicity has been reported in a few patients. In LUX-Lung 1 trial [46] , ocular effects were reported in 13% of patients who received afatinib (13% Grade 1-2, <1% Grade 3-4); similar results are reported in LUX-Lung 2 trial [47] , with 20% of ocular effects in patients received afatinib 40 mg/die and 28% in patients received afatinib 50 mg/die, with no event of Grade 3-4 toxicity. The two most common events were conjunctivitis and dry skin.
No data on the ocular toxicity of dacomitinib, an irreversible EGFR-TKI pan-human inhibitor, are available [48] .
Basti [49] has listed the most common ocular toxicities in patients on EGFR inhibitors: Squamous blepharitis: This condition typically presents with hyperemia of the eyelid margin; it often accompanies an acneiform rash.
Trichomegaly: Usually the lashes are elongated; in rare cases, the lashes may be misdirected inward and rub on the eyeball, causing significant irritation. Meibomitis: Patients with meibomitis complain of a burning sensation or mild redness of the eye, often accompanied by some mucus discharge. Dysfunctional tear syndrome: Dysfunctional tear syndrome can coexist with any of the above three conditions; the tear film is suboptimal and causes a dry, tired sensation of the eye as well as momentary sharp pain and/or burning.
The suggested treatment of these toxicities is mainly a warm compress, eyelid hygiene, corticosteroids, or anti-inflammatory medications. In case of keratitis or dry-eye syndrome, topical lubricants may be useful. It is important to specify that the steroideal therapy can be dangerous, should be administred on a short period of time (10 days) and should be considered only if a possible infectious has been eliminated. However, if important clinical manifestations are present, dose modification or interruption is recommended. Table 2 lists a clinical trial sequence that is performed in lung cancer using anti-EGFR inhibitors, with reported percentages of ocular toxicities.
As the data in Table 2 suggest, only a few trials specified mucous/cutaneous toxicities with ocular disorders. Only in the IDEAL1 trial [53] was performed an ophthalmic monitoring, which did not reveal any significant drug-related abnormalities or drug-related G3 or G4 events; G1 or G2 drug-related ophthalmic adverse events were reported in 43 patients (21%), but none required withdrawal from therapy. Mok et al. [54] (studying efficacy and safety of erlotinib in 1.242 East/South-east Asian patients) reported conjunctivitis, blepharitis, keratitis, eye pain, dry eyes, and corneal erosion. Ranson et al. [62] (studying gefitinib) reported conjunctivitis in 15.6% of patients; Baselga et al. [63] (also studying gefitinib) noted that one patient had a grade 3 epithelial defect in the cornea, caused by abnormal eyelash growth, and the patient was withdrawn from the study. Perez-Soler et al. [64] (studying erlotinib) noted that less than 10% of their patients exhibited signs of ocular toxicity and that none exceeded grade 2.
ALK inhibitors
The fusion oncogene, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), is present in approximately 5% of NSCLC tumors.
Crizotinib is an oral TKI that silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK. The efficacy of crizotinib in patients with locally advanced or metastatic ALK-positive NSCLC has been assessed in a two-part, phase I trial and a phase II trial [65] [66] . Patients enrolled into these studies had received prior systemic therapy, with the exception of 15 patients in the phase II trial, who had no prior systemic treatment for locally advanced or metastatic disease. In the phase I trial ALK-positive NSCLC was identified using the Vysis ALK Break-Apart FISH Probe Kit; in the phase II trial ALK-positive NSCLC was identified using a number of local clinical trial assays. The primary efficacy endpoint in both studies was Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST). In the phase I trial the Objective Response Rate was 61%, with 68 patients responders (median duration of response: 48.1 weeks); in the phase I trial the Objective Response Rate was 61%, with 71 patients responders (median duration of response: 48.1 weeks). In US crizotinib is approved by FDA for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test; in Europe EMA has approved crizotinib not in first-line, but only when the disease has already been treated before. Emerging data suggest that crizotinib may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the ROS1 oncogene [67] . Treatment-related visual disorders (including visual impairment, photopsia, blurred vision, vitreous floaters, photophobia and diplopia) were reported in 62% of crizotinib recipients enrolled in the phase I trial [65] or phase II trial [66] ; most of these events were grade 1 and usually started within 2 weeks of treatment initiation.
New drugs
The mitogen-activated protein kinase (MEK) pathway is a signal transduction pathway that ultimately leads to cellular proliferation. MEK-inhibitors are a novel class of molecules under investigation in multiple tumor types, including NSCLC. In particular, they seem to be active in patients with KRAS mutations. There are many compounds undergoing testing in clinical trials (e.g., GSK1120212, AZD6244, PD0325901).
Visual changes observed in subjects receiving GSK1120212 may include but are not restricted to: Table 2 Clinical trials performed in lung cancer using EGFR-inhibitors and ALK-inhibitors, with reported percentage of ocular toxicity.
Trial
No. patients Ocular effects LUX-lung 1 (afatinib) [46] 585 (33% Caucasian/66.1% Asian/0.9% others) 13% All grades; <1% grades 3-5 LUX-lung 2 (afatinib) [47] 129 (87% Asian/12% Whit/1% Black) 28% All grades TITAN (erlotinib) [50] 203 (13.8% Asian/86.2% Caucasian) N.A. BR.21 (erlotinib) [42] 485 (12.9% Asian/87.1% others) 9% All grades;1% grades 3-5 EURTAC (erlotinib) [51] 86 Caucasian N.A. SATURN (erlotinib) [52] 433 Caucasian N.A. TRUST (erlotinib) [54] 1.242 Asian 14% All grades IDEAL 1 (gefitinib) [53] 210 Asian 21% All grades ISEL (gefitinib) [55] 1.126 Asian N.A. INSTEP (gefitinib) [56] 100 (4% Asian/96% Caucasian) 5% All grades IPASS (gefitinib) [57] 607 Asian N.A. INTEREST (gefitinib) [58] 729 (21.1% Asian/75.4% Caucasian/1.4% Black/2.1% others) N.A. First-SIGNAL (gefitinib) [59] 159 Asian N.A. Northeast Japan study group: (gefitinib vs. Carboplatin-Paclitaxel) [60] 114 Asian N.A. WJTOG3405(gefitinib) [61] 87 Asian N.A. Phase II trial (dacomitinib vs. erlotinib) [48] 94 (24.5% Asian/75.5% Caucasian) N.A. Phase I crizotinib [66] 119 (29% Asian/62% Caucasian/3% Black/6% others) 62% All grades Phase II crizotinib [67] 136 (32% Asian/64% Caucasian/3% Black/1% others) 62% All grades
Gradual or immediate loss of vision including blind spots Temporarily or permanently blurred vision Dimness of vision Double vision Halo vision around lights Colorful spots or floaters Changes in color vision
Selumetinib (AZD6244) is an orally available, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinase; early phase clinical studies of selumetinib monotherapy showed target inhibition [68] and tumor response [69] ; in a phase II trial selumetinib monotherapy showed little clinical activity in an unselected pretreated population with NSCLC [70] . In a phase II study with selumetinib plus docetaxel versus placebo plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer [71] , although the addition of selumetinib to docetaxel as second-line treatment did not significantly improve overall survival, the combination resulted in clinically meaningful and statistically significant improvements in progression-free survival, response and patient-reported outcomes. Selumetinib was correlated with some ocular disorders, such as blurred vision, diplopia, visual disturbance, eyelid edema, increased lacrimation, subconjunctival hemorrhage, and retinal pigment epithelium detachment.
PHA-848125 is a potent inhibitor of the kinase activity of the CDK2/Cyclin A complex, showing activity also towards closely related CDKs (CDK1, CDK4, and CDK5) and TRKA [72, 73] . The antiproliferative effect of PHA-848125 was tested on a panel of 120 tumoral cell lines established from different solid tumors, including lung cancer, thymic carcinomas, leukemias and lymphomas [74] . In combination studies, PHA-848125 exhibited synergistic or more than additive activity when administered with docetaxel, topotecan or temozolomide, and additive effect when combined with bevacizumab, irinotecan, 5-FU and gemcitabine. Combinations were well tolerated; ocular toxicity was observed in rats after prolonged administration (P1 month) of PHA-848125. Bilateral retinal atrophy occurred from the dose of 16 mg/kg/day in females and at 24 mg/kg/day in males in the 4-week study. The same finding was seen in rats given the dose of 16 mg/kg/day for 3 cycles of 3 weeks + 1 week rest or 5 cycles of 2 weeks + 1 week rest. This effect did not regress after the 2-or 4-week recovery periods. The dose of 8 mg/kg/day, given for 4 consecutive weeks or cyclically for 3 months, was the NOEL for ocular changes. No retinal changes were seen in rats following administration of PHA-848125 for 7 consecutive days up to the highest dose (51.8 mg/kg/day).
For these patients, it is important from the beginning to have a baseline ophthalmologic examination including visual acuity and fundoscopy. Also useful are retinal photographs and a visual field examination (Fig. 1) .
Conclusion
There is no consensus or recommendation about routine ophthalmologic monitoring and management of ocular toxicity (Table 3). For anticancer agents that have the potential to induce ocular adverse side effects, a baseline ophthalmologic examination is recommended before starting treatment (e.g., visual acuity, tonometry, fundoscopy, color vision test, automated perimetry, retinal photographs) and during subsequent cycles of therapy. Some ocular toxicities can be diagnosed and graded by this routine examination whereas others (e.g., retinal detachment, altered visual acuity) require a dedicated ophthalmologic examination. In patients who experienced peripheral neuropathy during chemotherapy, a particular ophthalmological evaluation including an automated perimetry and a color vision test should be proposed to detect an asymptomatic optic neuritis. Many side effects can be managed just by dose interruption or dose modification with adequate supportive care. Anticipation of various treatment-related toxicities may provide the opportunity for clinicians to develop intervention strategies that could minimize or eliminate an expected side effect. There are many possible ways to manage ocular side effects that the patient can apply, including using a warm compress, eyelid hygiene, corticosteroids, or anti-inflammatory topical medications, or topical lubricants, and avoiding light exposure (dark room, sunglasses). The use of corticosteroids, valid therapeutical approach in many situations of ocular disorders, can be dangerous and should be restricted to non infectious complications. A possible choice for patients could be simply clinical observation. However, if symptoms do not resolve or residual symptoms are present, the patient should be promptly referred to an ophthalmologist.
In conclusion, ophthalmic complications induced by cytotoxic chemotherapy and target therapies are often underestimated because of the priority given to other life-threatening effects. An ophthalmic baseline examination prior to anticancer treatment and careful monitoring during treatment may lead to a reduction in ocular side effects when predisposed patients are screened and carefully examined during administration of treatment. An annual ophthalmologic evaluation should be proposed for patient treated with target therapy such as EGFR-TKIs and ALK-inhibitors in order to improve an early diagnosis of ocular disorders. All patients should be informed about possible visual disturbance and about the necessity of informing their oncologists as soon as they experience any ocular alteration. The possible reversal of some of these adverse events, if discovered in time, emphasizes how important it is for clinicians to be aware of these ocular reactions and suggest an immediate consultation with an ophthalmologist where warranted. Because of the complexity of this kind of malignancies, a multi-disciplinary approach should be improved between different specialists. It is very important that oncologists and ophthalmologists work together to prevent irreversible ocular toxicity and determine the true cause of visual disturbance, as part of multi-disciplinary effort. In fact, not all visual disturbances are related to primary ocular disorders because malignancy, metastases, or non-oncologic diseases can also simulate some symptoms.
Finally, new toxicity criteria including not only the intensity, but also the duration, should be introduced into the management of patients undergoing targeted therapies.
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